FDA approves Daiichi Sankyo ' s new first-line AML drug quizartinib with boxed warning for heart disorders
Patients with a rarer form of acute myeloid leukemia now have a frontline treatment option for the first time, thanks to the FDA’s approval of Vanflyta (quizartinib), Daiichi Sankyo announced late Thursday. Vanflyta has been approved for FLT3-ITD-positive AML patients in…#myeloid #fda #daiichisankyo #aml #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cardiology | Health | Heart | Leukemia | Men | Warnings